PharmaKnowl Consulting participated in the 11th Bioproduction Congress 2026, held on 22 September 2026 at Groupama Stadium in Lyon, France, with Mohammad Jobran, Principal Consultant & CEO, contributing to discussions on Saudi Arabia’s evolving biopharma and regulatory landscape.

During the congress, Mohammad took part in the International Panel on “Understanding the Saudi Biopharma Ecosystem: Opportunities and Realities,” offering an on-the-ground perspective on the Kingdom’s rapidly evolving biopharmaceutical landscape. The discussion explored the growing opportunities for international biotechnology, biopharmaceutical, and biomanufacturing companies looking to enter or expand in the Saudi market, including the country’s increasing focus on local pharmaceutical manufacturing, innovation, advanced therapies, and the development of a stronger life sciences ecosystem. The panel also addressed the practical considerations companies need to consider when entering the Kingdom, from understanding the regulatory environment and applicable SFDA requirements to developing an effective market-entry and commercialization strategy. Mohammad shared practical insights from PharmaKnowl’s experience supporting international life sciences companies in navigating Saudi Arabia’s regulatory and market landscape, helping participants better understand both the opportunities and the considerations involved in establishing a presence in the Kingdom.

Mohammad also hosted a workshop titled “Accelerated Regulatory Pathways to Saudi Arabia: New SFDA Programs by Development Stage.” The workshop provided an overview of newer accelerated regulatory pathways introduced by the Saudi Food and Drug Authority (SFDA) and discussed how these programs may support companies in developing their regulatory and market-entry strategies according to the stage of product development.

The sessions highlighted the importance of understanding Saudi Arabia’s regulatory environment early in the development and commercialization process, particularly for innovative biopharmaceutical products and advanced therapies.

PharmaKnowl Consulting continues to engage with global life sciences organizations and industry platforms to share practical regulatory insights and support companies seeking to establish and expand their presence in Saudi Arabia and the wider GCC region.